AlprolixTM is an approved drug (FDA (2014))
Compound class:
Peptide or derivative
Comment: AlprolixTM is a recombinant fusion protein combining the peptide for coagulation factor IX with an antibody Fc domain. The presence of the Fc domain increases protein half-life and extends the drug's therapeutic window.
|
| No information available. |
Summary of Clinical Use  |
| Designated as an orphan drug by the US FDA, this drug may be used as a prophylactic to reduce bleeding episodes in patients suffering from Hemophilia B. The benefit of this drug is its extended half-life compared to previous treatments, meaning that patients require less frequent injections. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Replaces the factor IX missing in hemophilia B patients, to restore clotting function and reduce pathological bleeding events. |
